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Abstract
Background: In Ethiopia, the leaves of Syzygium guineense have been found useful for the prevention and cure of
malaria, and demonstrated antiplasmodial activity in vitro. Nevertheless, no scientific study has been conducted to
confirm its antimalarial activity in vivo. Therefore, the objective of the study was to evaluate the antimalarial effect
of Syzygium guineense leaf extract in mice.
Methods: Inoculation of the study mice was carried out by using the malaria parasite, Plasmodium berghei. The
plant extract was prepared at 200, 400 and 600 mg/kg. Chloroquine and distilled water was administered to the
positive and negative control groups respectively. Parameters like parasitaemia, survival time and body weight were
determined following standard tests (4-day suppressive, Rane’s and repository tests).
Results: Syzygium guineense crude leaf extract displayed considerable (p < 0.05) parasite suppression at doses of 600
and 400 mg/kg in a 4-day suppressive test with chemosuppressive value of 59.39 and 49.09% respectively. S.
guineense crude leaf extract also showed dose-dependent schizontocidal activity in both the repository and curative
tests. The extract also prevented body weight loss and prolonged survival date of mice significantly (P < 0.05) at the
highest dose employed in the study. Qualitative chemical assay for S. guineense methanolic leaf extract revealed
that the plant is endowed with different plant secondary metabolites exemplified by terpenoids, alkaloids,
triterpenes, flavonoids, anthraquinones, tannins, glycosides, saponins and phenols.
Conclusion: Syzygium guineense leaf extract possess antimalarial activity in mice. The test substance was found to
be safe with no observable signs of toxicity in the study mice. The results of the present work confirmed the in
vitro antiplasmodial finding and traditional claims in vivo in mice. Therefore, Syzygium guineense could be regarded
as a potential source to develop safe, effective and affordable antimalarial agent.
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Background
Regardless of intensive efforts to get rid of malaria, the
infection remains to be among the top health problems
in Ethiopia [1]. Malaria, though widespread in tropical
Africa, the healthcare coverage of the continent in gen-
eral and the rural areas in particular is still inadequate.
People dwelling in this area have time tested experiences
regarding medicinal plants. As a result, people in the
countryside, wholly or partially, use medicinal plants for
prevention as well as cure of various disease conditions
especially malaria. People give predilection to use herbal
remedies due to the fact that traditional healers are eas-
ily accessible and generally respected by the community.
This could be also a result of inadequate knowledge of
the rural people regarding the modern healthcare
institutions coupled with their belief in herbal remedies
as being more affordable, safer and effective compared
to the modern medicine [1–3].
In Ethiopia, malaria is the major cause of morbidity
and mortality, with approximately 5–10 million cases
per year. The disease causes not less than 60,000 deaths
every year and accounts for about 17% of outpatient
visits to health organizations, 8% of admissions and 29%
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of inpatient deaths [4, 5]. Furthermore, P. falciparum
malaria parasite has recently developed resistance to al-
most all of the currently available medications used to
treat the infection [6–8].
Syzygium guineense is a large evergreen flowering plant
(family Myrtaceae). The plant is found widespread in the re-
gions of Australia, Asia and Africa including Ethiopia [9].
Historically, antimalarial drug therapy is closely associ-
ated with traditionally used medicinal plants contributing
like quinine; the first plant derived natural product (identi-
fied from Cinchona bark) is still employed in antimalarial
therapy. Phytochemical compounds such as alkaloids, also
found in the leaves of S. guineense, are commonly
implicated for their antiplasmodial activity of many plants
including Cinchona tree from which quinine, the first
antimalarial drug, was isolated [10, 11]. In Ethiopia, leaf
decoction of S. guineense is being used traditionally to
treat malaria [12, 13].
Other secondary metabolites present in S. guineense im-
plicated for their antimalarial activity include: Terpenoids
[14–16], Phenols [17], Anthraquinones [18, 19], and
Flavonoids [20]. S. guineense leaves are also recognized by
their immunomodulatory [21], anti-oxidant, and anti-
inflammatory properties [22].
Furthermore; the members of the genus Syzygium are well
recognized for their antimicrobial, anti-inflammatory, anti-
malarial and larvicidal effect in mosquito vector [23]. The
family Myrtaceae [24] and different species of Syzygium have
shown promising antimalarial activity in vitro [25].
Despite the plant being endowed with the aforemen-
tioned secondary metabolites known for their antimalar-
ial activity and in vitro claims, information regarding its
in vivo antimalarial efficacy is extremely lacking. There-
fore, this study was aimed in evaluating the traditional
claim as well as reported in vitro efficacy of S. guineense
in vivo in mice.
Methods
Collection and identification of the plant material
The fresh leaves of S. guineense (Wild) D.C. were
collected near the town of Gondar in North Gondar ad-
ministrative zone, Ethiopia, in February 2015. S.
guineense as a potential medicinal plant was selected de-
pending on the evidence provided by herbalists in
Northwest Ethiopia. The antimalarial plant S. guineense
was kindly authenticated by a taxonomist at the Ethiop-
ian National Herbarium, Addis Ababa University and
the Voucher specimen (voucher number ST02/2015) de-
posited for future reference.
Experimental animals
Albino mice of either sex (25–30 g) were used for this
study. All the study mice were sustained under standard
environment (Temperature of 22 ± 3 °C, Relative
Humidity of 50–70% and 12 h light/dark cycle), with
food and water ad libitum. Mice were allowed to adapt
themselves to the experimental environment for 7 days
prior to the initiation of the actual experiment. All the
experimental protocols were evaluated and approved by
the institutional review board of the university.
Parasite isolate
For the in vivo evaluation of S. guineense leaf extract,
chloroquine sensitive P. berghei ANKA strain was used.
The malaria parasite, P. berghei, was kindly provided by
Ethiopian Health and Nutrition Research Institute
(EHNRI) and was sustained by serial passage of blood
from infected mice to non-infected ones on weekly basis.
Extraction procedure
Fresh matured leaves of S. guineense (Wild) D.C. were
collected, washed, air dried under shade and grinded
using mortar and pestle to coarse powder. A total of
400 g powder was extracted by maceration for 72 h,
filtered with wattman filter paper (150 mm size), and the
residue extracted further two times by maceration with
the same duration (72 h each). Finally, the combined
filtrate was kept in an oven (40 °C) for concentration.
Further drying process was carried out in a desiccator
for removal of water. Finally, the dried extract was main-
tained at −4 °C till the beginning of the actual
experiment.
Phytochemical analysis of the crude extract
A preliminary phytochemical study of S. guineense leaf ex-
tract was performed using standard procedures [12, 13].
Parasite inoculation
Blood were collected from the tail veins of previously P.
berghei infected donor mouse having a parasite load of
30–37% to infect the mice. Subsequently, the blood was
diluted in normal saline (0.9%) so that the final suspen-
sion contained 107 infected red blood cells in each
0.2 ml of the preparation. Accordingly, mice were inocu-
lated with 107P. berghei parasitized RBCs via the intra-
peritoneal route [26–28].
Acute toxicity study
The safety of the extract when taken acutely was per-
formed according to the OECD guideline 425. A fixed
dose of 2000 mg/kg body weight of S. guineense crude
leaf extract was administered to a single mouse via the
oral route by gavage. Before the administration of the
test substance, mice were prohibited from free access to
food for 3 h. Similarly, food was with held for 1 h after
extract administration. Following administration of the
crude extract, mice were closely observed for an hour,
occasionally for 4 h in a day (24 h) for a total of 14 days.
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Mice were closely monitored for the occurrence of any
behavioral abnormalities indicated by decreased appetite,
tremor, convulsion, increased saliva secretion, lacrima-
tion, diarrhea, death as well as other manifestations of
toxicity. In view of the fact that no death of the study
mice at the test dose of 2000 mg/kg were observed, add-
itionally 4 mice were sequentially dosed the same dose
of the extract [29].
Test on early malaria infection
The suppressive activity of S. quineense crude leaf ex-
tract was evaluated according to the Peter’s suppressive
assay (4- day suppressive test). The Peter’s test is widely
used in screening of plant extracts for their in vivo anti-
plasmodial activity via the use of two important parame-
ters (blood parasitemia and mean survival time of mice)
[26, 27, 30]. Mice were infected with 1 × 107P.berghei
and kept in the same compartment before being
assigned in 5 groups.
Following the infection, mice were arbitrarily distrib-
uted in to 3 extract treated & 2 control groups (each
group containing 5 mice in a cage).
The crude leaf extract was administered at 200, 400
and 600 mg/kg and chloroquine 10 mg/kg body weight
via the oral route once per day dose with gavage.
After three hours of parasite inoculation, mice were
treated daily for 4 consecutive days. After treatment is
completed (4th day), thin blood smears were made by
drawing blood from the tail of each mouse. Accordingly,
each smear was fixed in methanol, and giemsa (10%)
stained for subsequent determination of parasitaemia
with a microscope (via counting 4 fields of about 100
RBCs in each field).
The difference between the mean value of the negative
control group and those of the extract treated groups
were determined to evaluate the activity of S. quineense
extract in mice [28, 29, 31, 32].
Activity ¼ 100–½Mean parasitaemia treated
=Mean parasitaemia in negative control  100
Percent parasitaemia ¼ ½No: of parasitized RBC
=Total no: of RBC counted  100
Monitoring of body weight changes
Body weight of each mouse was recorded before infection
(day 0) and on (day 4) using sensitive digital balance.
Monitoring of mean survival time
Mortality of the study mice was closely observed daily
and the number of days from the time of infection with
P. berghei up to the incidence of death was recorded for
every mouse in both the treatment and control groups
during the follow up period. Mean Survival Time (MST)
of all mice were determined using the formula [28]:
MST ¼ Sum of survival time of all mice in a group daysð Þ
=Total number of mice in that group
Evaluation of the extract on residual P. berghei infection
The residual infection protocol described by Peter [32]
was employed to evaluate the prophylactic activity of the
extract. Consequently, either sex of 25 mice were
weighed and randomized into five groups of five mice
each. Group I received 0.5 ml distilled water per kg body
weight. Groups II, III and IV received 200, 400 &
600 mg/kg body weight of S. guineense extract orally
respectively. The standard drug, (10 mg/kg/day chloro-
quine), was administered to Group V. Treatment contin-
ued for three successive days (from D0 - D2). On the 4
th
day (D3), mice were infected with 1 × 10
7P. berghei in-
fected red blood cells. Finally, after 72 h, parasitaemia
was determined via blood smear.
Evaluation on established infection (Rane’s test)
The curative potential of S. guineense was evaluated by
employing the method described by Ryley and Peters
(1970). On the 1st day (day 0), mice were injected intraper-
itoneally with a standard inoculum of 1 × 107P. berghei
infected RBCs. Seventy-two hours later, following con-
firmation of parasitaemia, the mice were randomly
assigned into two control and three test groups, each
group containing five mice per cage. The test groups were
sequentially treated with the prepared leaf extract of S.
guineense (200, 400 and 600 mg/kg/day). The standard
drug (10 mg/kg/day chloroquine) and vehicle (0.5 ml dis-
tilled water) was administered to the positive and negative
control groups respectively. Treatment continued for 5
consecutive days at a single dose per day. Geimsa stained
(10%) thin blood film (prepared by drawing blood from
the tail vein of each mouse) was examined microscopically
to determine the percentage of parasitaemia.
Statistical analysis
Results of the study were presented as mean ± SEM.
Data was analyzed using SPSS version 20. Statistical sig-
nificance was determined by One-way ANOVA coupled
to Tukey’s HSD technique to compare result between
doses and among treatment and control groups. For all
the data obtained, the result was considered significant
at 95% confidence level and P-value < 0.05.
Results
Phytochemical analysis
Preliminary phytochemical study of the extract of S. gui-
neense (Wild) DC leaves revealed the presence/absence
of plant secondary metabolites shown in Table 1.
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Acute toxicity
S. guineense leaf extract didn’t cause death of the study
mice at the limit dose of 2 g/kg. Similarly, both physical
and behavioral observations of the study mice also did
not point out any visible signs of toxicity. This indicates
that the LD50 of the extract is above 2 g/kg.
In vivo antimalarial activity tests
Test on early malaria infection (the 4-day suppressive test)
Leaf extract of S. guineense reduced parasitaemia level in
the study mice dose-dependently at all tested doses. The
crude extract, at the highest doses employed, (400 and
600 mg/kg per day) exhibited 49.09 and 59.39% chemo-
suppression respectively. Average parasite load at these
doses were much lower (p < 0.05) than that observed in
the untreated mice. The extract was also able to
suppress parasitaemia (26.67%) at 200 mg/kg). The
complete data is presented in Table 2.
The comparison analysis indicated that the extract
prevented weight loss significantly (p < 0.05) at all tested
doses compared to distilled water treated control group.
The increase in body weight was found to be highest at
the largest dose used in the study (9.82%) (Table 3).
The extract prolonged mean survival period of the
study mice (from 8 ± 1.73 to 10.8 ± 2.59 days). The
corresponding vehicle treated mice survived only for 7 ±
0.70 days. Though much lower than the chloroquine-
treated group (which lived for 28 days), the extract at
600 mg/kg was capable of significantly increasing (P <
0.05) survival date of mice (Table 4).
Test on prophylactic activity (repository test)
S. guineense extract exhibited a dose-dependent reduc-
tion in parasitaemia level in mice. At the highest dose
used in the study (600 mg/kg body weight), the crude
extract demonstrated a considerable (p < 0.05) antiplas-
modial activity compared to the vehicle treated control
group. Average chemosuppression at this dose was
48.57% which is lower than that exhibited by the stand-
ard drug (72.85%).
Test on established malaria infection (curative test)
S.guineense leaf exerted a considerable (P < 0.05) curative
effect at 600 and 400 mg/kg. Mean parasite counts at
these doses were 6 ± 0.44 and 13 ± 0.72 respectively. The
extract at 200 mg/kg was also capable of decreasing
parasite load to 17 ± 0.66 while, the mean parasite count
in the untreated control group was 43 ± 0.76 (Table 5).
Parasite load in extract treated mice was lower than that
of the untreated mice indicating its pharmacological ef-
fect against established malaria infection. Nevertheless,
this noticeable antiplasmodial effect of S. guineense was
not comparable to the standard drug that reduced mean
parasite density to 2 ± 0.37.
S. guineense leaf extract treated mice lived for 15 ±
0.44, 13 ± 0.14, and 8 ± 0.72 days at 600, 400 and
200 mg/kg/day dose respectively. On the contrary, mice
receiving vehicle lived for 7 ± 0.22 days only. Chloro-
quine treated mice displayed the longest mean survival
time (28 ± 0.56 days) which is significantly (P < 0.05)
high compared to mice in both extract and distilled
water treated groups.
Discussion
In vivo screening of medicinal plants for their potential
antimalarial activity is usually performed with a rodent
malaria parasite, particularly P. berghei, which has been
used extensively in the discovery and development of













Key: (+) = presence, (−) = absence
Table 2 Effects of S. guineense crude leaf extract on early infection
Treatment Group Dose % Parasitaemia % chemosuppression
DW (negative control) Group I 0.5 ml 33 ± 2.62 _
S. guineense leaf extract Group II 200 mg/kg 24.20 ± 3.80ns 26.67
Group III 400 mg/kg 16.80 ± 5.54* 49.09
Group IV 600 mg/kg 13.40 ± 1.96* 59.39
Chloroquine (standard) Group V 10 mg/kg 0.80 ± 0.37*, **, *** 97.57
DW distilled water
Values are indicated as means ± SEM, n = 5, ns = not significant, * = p < 0.05 compared to negative control, ** = p < 0.05 compared to 200 mg/kg extract, *** = p <
0.05 compared to 400 mg/kg extract
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several conventional antimalarial drugs exemplified by
halofantrine, chloroquine, mefloquine and more recently
artemisinin derivatives [27].
Therefore, in the current study, antimalarial activity of
S.guineense was evaluated using P. berghei, which
produces disease similar to those of human plasmodium
infections, for the prediction of treatment outcomes
[31]. A standard antimalarial drug suppresses parasit-
emia significantly [33] which is in agreement with the ef-
fect of chloroquine in this study that achieved 97.57%
suppression of the growth of P. berghei (the complete
data is available in Table 2).
The 4-day suppressive assay is a standard test uni-
versally used for antimalarial screening, and the deter-
mination of percent inhibition of parasite growth is
regarded as the most dependable parameter in anti-
malarial drug discovery [34]. In the 4-day suppressive
test on P. berghei infected mice, S. guineense crude
leaf extract exhibited dose-dependent activity at dif-
ferent doses employed in the study. The result is
similar to other in vivo studies [33, 35–38]. A signifi-
cant (P < 0.05) parasite suppression was observed at
doses of 600 and 400 mg/kg compared to the
negative control group. It is important to note that
the crude extract at the lowest dose (200 mg/kg) also
exhibited parasite suppression though not statistically
different from the control group indicating that the
extract is endowed with antiplasmodial activity and
supports its traditional claim as antimalarial herbal
remedy in Africa [23, 24].
The methanolic leaf extract of S.guineense also dis-
played antimalarial effect against residual infection of
the parasite at all tested doses. The result of the study
clearly indicated dose-dependent parasite suppression of
S.guineense leaf extract even though not comparable
with the chloroquine treated control group which
suppressed 72.85% (Table 6). The low activity of the ex-
tract observed in the repository test when compared to
the effect against early infection may be due to rapid
clearance of the active agent by the liver.
The crude extract was also capable of increasing mean
survival time (MST) of the study mice indicating that it
suppressed the growth of P. berghei. Moreover; the
extract was capable of reducing the overall pathological
effects of this parasite in mice. It is also good to note
that the survival time of the study mice receiving 600 mg/kg
of the extract was significantly (p < 0.05) high as compared
to those groups receiving 200 and 400 mg/kg as well as dis-
tilled water treated control mice. This may suggest a dose-
dependent schizontocidal activity of the extract.
Body weight loss is one feature of rodent malaria in-
fection. The extract not only prevented body weight loss
in mice but also increased the weight of the study mice
(Table 3). This indicates that other than direct parasiti-
cidal effects, the plant may possess other pharmacologic
benefits to the host: acting as analgesics, antipyretics,
immune stimulators or the extract may contain appetite
enhancing agent (s) [39].
Table 3 Effects of S. guineense leaf extract against weight loss in early malaria infection
Treatment Group Dose Wt. D-0 Wt. D-4 % change
DW (negative control) Group I 0.5 ml 24.84 ± 1.55 23.96 ± 1.29 −3.54
S.guineense leaf extract Group II 200 mg/kg 23.90 ± 1.13 24.88 ± 1.24 4.10*
Group III 400 mg/kg 27.38 ± 0.66 27.76 ± 0.65 1.38*
Group IV 600 mg/kg 26.46 ± 1.17 29.06 ± 0.74 9.82*
Chloroquine (standard) Group V 10 mg/kg 25.39 ± 1.62 26.06 ± 1.43 2.63*
DW distilled water
Values are expressed as means ± SEM, n = 5, * = p < 0.05 compared to negative control
Table 4 Effect of S. guineense extract on survival time in the
suppressive test
Treatment Group Dose Mean Survival
times (days)
DW (negative control) Group I 0.5 ml 7 ± 0.70
S. guineense leaf extract Group II 200 mg/kg 8 ± 1.73ns
Group III 400 mg/kg 8.2 ± 1.30ns
Group IV 600 mg/kg 10.8 ± 2.59*
Chloroquine (standard) Group V 10 mg/kg 28 ± 0.00*, **, ***, ****
DW distilled water
Values are expressed as means ± SEM, n = 5, ns = not significant, * = p < 0.05
compared to negative control, ** = p < 0.05 compared to 200 mg/kg, *** = p <
0.05 compared to 400 mg/kg, **** = p < 0.05 compared to 600 mg/kg of
the extract





time (days)Pre –(D3) Post –(D7) Rx
Control (−ve) - 19 ± 0.62 43. ±0.76 7 ± 0.22
Extract 200 18 ± 0.63 17 ± 0.66 8 ± 0.72
400 17 ± 0.73 13 ± 0.72* 13 ± 0.14*
600 16 ± 0.81 6 ± 0.44* 15 ± 0.44*
Chloroquine 10 10 ± 0.83 2 ± 0.37* 28 ± 0.56*
Values are expressed as means ± SEM, n = 5, * = significant at p < 0.05
compared to the negative control
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Phytochemical screening of S. guineense leaf extract re-
vealed the presence of alkaloids, terpenoids, anthraquinones,
flavonoids, tannins, saponins, glycosides, triterpenes and
phenols (Table 1). Alkaloids, also present in this plant, are
generally known for their antiplasmodial activity of many
plants including Cinchona bark from which quinine was
isolated [21, 22]. Terpenoids have been implicated for
their antiprotozoal and antimalarial activities in many
pharmacological studies [21, 22]. S. guineense leaf also
contain phenols known for their anti-oxidant and other
diverse physiological properties: anti-carcinogenic, anti-
inflammatory and anti-parasitic activities [10]. Anthraqui-
nones, also found in this plant, is identified as active anti-
malarial compound [11, 14]. Flavonoids, also present in S.
guineense leaf extract, are other potential antimalarial
compounds believed to act by inhibiting the fatty acid bio-
synthesis (FAS II) of the malaria parasite [14]. S. guineense
leaf possesses potential immunomodulatory [21], anti-
oxidant [15, 40], anti-inflammatory and analgesic effects
[22, 41]. S. guineense extract may also act via another
unknown mechanism that may contribute for its antiplas-
modial effect.
Therefore, these observed schizontocidal activities of
S. guineense in mice could be attributed to the diverse
classes of phytochemical compounds present in the leaf.
On the other hand, the plant may be endowed with un-
discovered (unknown) antimalarial compound (s) that
could be used for the production of relatively safe, ef-
fective and affordable antimalarial agent.
Conclusion
The present work has confirmed the efficacy of S. gui-
neense supporting its traditional use against malaria. The
results also indicated that the test substances have wide
safety of margin making it potential source for the devel-
opment of safer and cost-effective alternative drug in the
treatment and cure of malaria.
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